TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4
|
|
- Pierce Freeman
- 5 years ago
- Views:
Transcription
1 1 TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA
2 FDA APPROVES IMPELLA FOR HIGH-RISK PCI 2 Impella is the only hemodynamic support device proven safe and effective in elective and urgent High-Risk PCI patients Impella is designed to protect the patient hemodynamically during a high-risk procedure
3 IMPELLA DEVICE INDICATION & SAFETY INFO. 3 INDICATIONS FOR USE Protected PCI The Impella 2.5 and Impella CP Systems are temporary ( 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 and Impella CP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events. Cardiogenic Shock The Impella 2.5, Impella CP, Impella 5.0, and Impella LD Catheters, in conjunction with the Automated Impella Controller (collectively, "Impella System Therapy"), are temporary ventricular support devices intended for short term use ( 4 days for the Impella 2.5 and Impella CP, and 6 days for the Impella 5.0, and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP). The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function. Important Risk Information for Impella devices CONTRAINDICATIONS The Impella 2.5, Impella CP, Impella 5.0 and Impella LD are contraindicated for use with patients experiencing any of the following conditions: Mural thrombus in the left ventricle; Presence of a mechanical aortic valve or heart constrictive device; Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less); Moderate to severe aortic insufficiency (echocardiographic assessment graded as +2); Severe peripheral arterial disease precluding placement of the Impella System; Significant right heart failure*; Combined cardiorespiratory failure*; Presence of an Atrial or Ventricular Septal Defect (including post-infarct VSD)*; Left ventricular rupture*; Cardiac tamponade* * This condition is a contraindication for the cardiogenic shock indication only. POTENTIAL ADVERSE EVENTS Acute renal dysfunction, Aortic valve injury, Bleeding, Cardiogenic shock, Cerebral vascular accident/stroke, Death, Hemolysis, Limb ischemia, Myocardial infarction, Renal failure, Thrombocytopenia and Vascular injury In addition to the risks above, there are other WARNINGS and PRECAUTIONS associated with Impella devices. Visit to learn more.
4 DATA SUPPORTING PROTECTED PCI INDICATION 4 Scientific Evidence to Support PMA Applications* Total Number of Patients in the Cohort Number of Impella Protected PCI Patients Severely Reduced LVEF <35% Protect I Protect II U.S. Impella Registry 1, Literature review 2, Mild, Moderately Reduced LVEF >35% cvad Registry Study / 229 LVEF< 35% LVEF> 35% Total 5,024 2,403 * Patient data may be provided in multiple PMA applications
5 5 PROTECTED PCI WITH IMPELLA CLINICAL DATA & GUIDELINES
6 GROWING POPULATION APPROPRIATE FOR PCI 6 Surgical Ineligibility Prior Cardiac Surgery Heart Failure Diabetes Advanced Age Unstable Angina/NSTEMI Renal Insufficiency Patient Comorbidities Protected PCI Patients Complex Coronary Artery Disease Multi-vessel Disease Distal Left Main Disease Complex Lesions (bifurcations, calcification) CTO Retrograde Hemodynamic Compromise Mild, Moderate, Severely Depressed Ejection Fraction High LVEDP Protected PCI with Impella FDA Indicated Safe & Effective for High Risk PCI
7 Symptoms Symptoms PATIENTS MOST APPROPRIATE FOR REVASCULARIZATION 7 Coronary Revascularization Appropriateness Guidelines ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 1 Heart Failure Angina High Risk Findings on Noninvasive Study CCS Class III or IV Angina Symptoms Med. Rx Class III or IV Max Rx A A A A A Class I or II Max Rx A A A A A Asymptomatic Max Rx U A A A A Class III or IV No/min Rx A A A A A Class I or II No/min Rx U A A A A Asymptomatic No/min Rx U U A A A Coronary Anatomy CTO of 1 vz.; no other disease 1-2 vz. disease; no Prox. LAD 1 vz. disease of Prox. LAD 2 vz. disease with Prox. LAD 3 vz. disease; no Left Main Protected PCI Patients = More Heart Failure More Angina More Complex = More likely to be appropriate Stress Test Med. Rx High Risk Max Rx A A A A A High Risk No/min Rx A A A A A Int. Risk Max Rx A A A A A Int. Risk No/min Rx U U A A A Low Risk Max Rx U A A A A Low Risk No/min Rx I U A A A Coronary Anatomy CTO of 1-vz; no other disease 1-2-vz. disease; no prox. LAD 1-vz. disease of prox. LAD 2-vz. disease with prox. LAD 3-vz. disease; no left main A = Appropriate, U = Uncertain, I= Inappropriate Complexity A = Appropriate, U = Uncertain, I= Inappropriate Complexity 1. Patel MR, et al, J AM Coll Cardiol. 2012;59(9);
8 PATIENT CHARACTERISTICS OF HIGH RISK 8 REVASCULARIZATION STUDY SYNTAX 1 Stent vs. CABG (n=903) HIGH RISK PCI STUDY PROTECT II 2,3 Impella 2.5 vs. IABP (n=427) LVEF 35% (%) ~2 100 CHF (%) 4 87 Unstable Angina Diabetes (%) Prior MI (%) Prior PCI 0 40 Prior CABG 0 34 Age (Mean±SD) 65±10 67±11 Not Surgical Candidates (%) 0 64 * * 64% of patients determined inoperable by surgical consult or refused surgery. Remaining 36% determined not surgical candidate by treating physician. 1.Serruys PW et al., N Engi J Med. 2009;360: Dangas et al., Am. Journ of Cardiol. 2014: 113(2): Pershad, et al., Am J Cardiol Sep 1;114(5):657-64
9 Anatomic Risk REVASCULARIZATION STRATEGY BY RISK CATEGORY 9 Surgical Risk Low Medium High Often inoperable Low PCI PCI PCI Medium CABG or PCI PCI or CABG Support & PCI Protected PCI FDA Indicated Safe & Effective High CABG CABG or PCI Support & PCI ACC/AHA PCI Guidelines 1,2 SYNTAX Study 1. Levine GN, et al. J Am Coll Cardiol, 2011 Dec 6;58(24):e44-122, 2 Amsterdam EA, et al. Circulation Dec 23; 130(25):e
10 HEMODYNAMICS OF PROTECTED PCI 10 Case Example* 66 yo male 85% SVG Last patent conduit EF = 30% NYHA Class IV Prior CABG Prior PCI Hemodynamically stable Not Surgical Candidate MAP 110 mmhg MAP 86 mmhg Impella 2.5 On No Impella Simulated Arterial Pressure Tracings 1-8% -10% -12% 97 mmhg -15% -23% -51% 42 mmhg Case Balloon Start Inflation 1. Physiologic computational modeling, Am J Physiol 1991;260 (HCP 29): H146-H157 * Not all patients will experience the same clinical outcomes or hemodynamic responses 15 sec 30 sec 45 sec
11 IMPELLA SUPPORT INCREASES ARTERIAL PRESSURE 11 U.S. Impella Registry Data 1 N=148 Systolic Pressure 119±25 Pre- Impella p< % 139±27 On Impella Diastolic Pressure 64±15 Pre- Impella p< % 81±19 On Impella 83±18 Pre- Impella Mean Pressure p< % 101±20 On Impella 1. Maini et al,.catheter Cardiovasc Interv Nov 1;80(5):717-25
12 IMPELLA DEVICES MAY IMPROVE CORONARY PERFUSION PRESSURE 1 12 Distal CPP* Effective CPP* LVEDP Diastolic Aortic Pressure (N=11) (N=11) (N=11) (N=11) % % % % (p<0.001) (p<0.001) (p<0.002) (p<0.001) P2 Flow P8 Flow P2 Flow P8 Flow P2 Flow P8 Flow P2 Flow P8 Flow Data from patients with critical coronary stenosis IABP has demonstrated no increase in CPP* distal to lesion 2 1. Alqarqaz, et.al. Circ Cardiovasc Interv. 2018;11:e Kern, et.al., Circulation 1993;87: *(CPP) Coronary Perfusion Pressure
13 HALF AS MANY HYPOTENSIVE EVENTS PER PATIENT WITH PROTECTED PCI 13 Hypotensive Events per Patient N = p= % Reduction 0.45 Protect II FDA PMA data Hypotensive event defined as MAP < 65mmHg IABP Impella FDA Randomized Controlled Trial Protect II
14 IMPELLA MAINTAINS PATIENT HEMODYNAMICS ALLOWING FOR MORE COMPLETE REVASCULARIZATION 14 Procedural Decrease in Arterial Pressure from Baseline IABP Impella N = Vessel Treated 2 Vessels Treated 3 Vessels Treated -2.7% -8.5% -7.6% p <0.001 p =0.007 p =0.026 Baseline Protected PCI -13.1% -14.9% Kovacic, et al. J Interv Cardiol Feb;28(1): % FDA Approved Randomized Controlled Trial Protect II
15 MORE COMPLETE REVASCULARIZATION LEADS TO REDUCED ADVERSE EVENTS 15 MACCE at 90 Days Protect II, Both IABP and Impella Arms, All Patients 33.8% p= % 17.0% N=157 N=215 N=53 1 Vessel Treated 2 Vessels Treated 3 Vessels Treated O'Neill, PROTECT II Abstract, Presented at Transcatheter Cardiovascular Therapeutics 2013 FDA Approved Randomized Controlled Trial Protect II
16 MACCE (%) IMPELLA REDUCES PERI & POST PROCEDURAL MACCE 16 MACCE MACCE = Death, Stroke, MI, Repeat revasc. IABP N=211 29% reduction In MACCE 15 Impella N= p= Time Post Procedure (day) Dangaset al, Am. Journ of Cardiol. 2014: 113(2):222-8 FDA Approved Randomized Controlled Trial Protect II
17 IMPELLA REDUCES MACCE WITH MORE COMPLETE REVASCULARIZATION 17 MACCE at 90 Days 35.0% p= % 28.5% p= % Reduction 15.9% IABP N=80 Impella N=77 IABP N=130 Impella N=130 1 Vessel Treated 2 or 3 Vessels Treated Protect II FDA PMA data ULM Included in 2 or 3 Vessels Protect II Study
18 COST EFFECTIVENESS OF PROTECTED PCI 18 Reduced Length of Stay Total Days in Hospital 1,3 Less Readmissions from Repeat Procedures 9.0 p= days or 22% 12.4% p= % Reduction % N=211 N=216 N=211 N=216 IABP Impella IABP Impella Median days in hospital; index stay through 90 days, N=427, Readmissions N= Gregory, O Neill, et al. American Health & Drug Benefits 2013 Mar;6(2): Gregory, et al. Managed Care Medicine, Feb Maini, et al. Expert Rev Pharmacoecon Outcomes Res Jun;14(3):403-16
19 HIGH RISK PATIENTS MAY BENEFIT FROM PROTECTED PCI LVEF Improvement Post Protected PCI 19 2 Italian Ctrs Study 1 (n=10) 41±13 Protect I 2 (n=16) 31±7 32% p= ±6 31% 34±11 p=0.003 Pre-PCI Follow-up Pre-PCI Follow-up U.S. Impella Registry 3 (n=175) 30±15 17% 35±15 p< ±9 Protect II 4 (n=175) 22% 33±11 p<0.001 Pre-PCI Follow-up Pre-PCI Follow-up 1. Burzotta et al. Cardiovasc Med 2008 Oct;9(10): ; 2. Dixon et al. JACC Cardiovasc Interv Feb;2(2):91-6; 3. Maini et al,.catheter Cardiovasc Interv Nov 1;80(5): ; 4.O Neill et al. Circulation Oct 2:126(14):
20 IMPROVEMENT IN QUALITY OF LIFE POST PCI 20 NYHA Class Improvement Post Procedure p< % 58% Reduction in Class III,IV 8% 18% Class IV 45% 30% Class III Class II 31% 44% Class I 7% Baseline 90 days N=223 patients from Both Arms of Protected II Trial with NYHA measurements available at baseline and 90 days 1 O Neill WW et al. Circulation Oct 2:126(14): FDA Approved Randomized Controlled Trial Protect II
21 IMPROVEMENT IN QUALITY OF LIFE POST PCI 21 LVEF Improvement Post Protected PCI NYHA Class Improvement Post Procedure Protect II (n=175) p< ±11 17% 58% Reduction in Class III,IV 8% 18% p<0.001 Class IV 22% 45% 30% Class III 27±9 Class II 31% 44% Class I Pre-PCI Follow-up 7% Baseline 90 days O Neill WW et al. Circulation Oct 2:126(14): IMP v.4 N=223 patients from Both Arms of Protected II Trial with NYHA measurements available at baseline and 90 days FDA Approved Randomized Controlled Trial Protect II
22 ADDITIONAL IMPELLA SAFETY ENDPOINTS 1 22 IABP Control Arm (n=210) Impella Protected PCI (n=215) p-value Aortic Valve Damage 0 0 NA Vascular Complications 2 1.9% 1.4% Acute Renal Dysfunction 4.8% 4.2% (Total Contrast media) 3 (241 ml) (267 ml) (0.036) 1. O Neill WW et al. Circulation Oct 2:126(14): Vascular complications from Protect II RCT = Cardiac, thoracic, or abdominal operation, or vascular operation for limb ischemia. 3. Acute renal dysfunction was numerically lower even with additional contrast media in the Protected PCI with Impella arm of Protect II RCT
23 CLINICAL GUIDELINES FOR IMPELLA 23 Protected PCI 2014 AHA/ACC Guideline for the Management of Patients With Non ST- Elevation Acute Coronary Syndromes. Circulation Revascularization in Heart Failure: Class I Revascularization strategy based on degree, severity, & extent of CAD; cardiac lesions; extent of LV dysfunction; prior revascularization. PVADS: Large amount of ischemic territory/poor LV function 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC High risk patients: Class IIb CLASS III: HARM without Hemodynamic support; for PCI at hospitals without on-site cardiac surgery Categories referencing Impella include Percutaneous LVAD, PVAD, Non-durable MCS, TCS and percutaneous MCSD Reimbursement and coding information: Inpatient Hospital = ICD.9 Code 37.68, commonly MS-DRG 216/217 Physician = CPT codes (insertion), (removal), (repositioning) Additional Guidelines 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC PCI and Cardiogenic Shock: Class I Use of Mechanical Circulatory Support: American Heart Association. Circulation 2012 Acutely decompensated heart failure patients: Class IIa 2013 Int l Society for Heart & Lung Transplantation Guidelines for Mechanical Circulatory Support. Jnl of Heart & Lung Transplantation Temporary mechanical support for patients with multi-organ failure: Class I 2013 ACCF/AHA Guideline for the Management of Heart Failure, JACC Bridge to Recovery or Bridge to Decision for patients with acute, profound hemodynamic compromise: Class IIa 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation STEMI and Cardiogenic Shock: Class IIb STEMI and urgent CABG: Class IIa
24 CONCLUSIONS Candidates are hemodynamically stable, higher risk patients that have depressed LVEF, complex CAD, & co-morbidities 2. Higher risk patients are appropriate for revascularization according to AUC criteria; a heart team should determine PCI or CABG 3. Impella is the only hemodynamic support device proven safe and effective in elective and urgent High-Risk PCI patients 4. Benefits from a Protected PCI may include: More complete revascularization with reduction in MACCE Reduction in symptoms and class of heart failure Improvement in LVEF post procedure Reduction in days in the hospital Reduction in readmissions due to fewer repeat procedures 5. Clinical guidelines and the FDA approval support the use of Impella for Protected PCI in this higher risk patient population
25 INCOMPLETE REVASCULARIZATION IS COMMON 25 Incomplete Revasc Complete Revasc 69% 31% 42% 58% 46% 54% 43% 57% 37% 63% NY PCI 2003 ARTS I 1997 ARTS II 2003 SYNTAX PCI SYNTAX CABG
26 COMPLETE REVASCULARIZATION VS. INCOMPLETE 26 SYNTAX Study Farooq et al, JACC 2013 ACUITY Study Rosner G et al. Circulation % 26.8% p<0.001 p<0.001 p< p< % 15.7% 17.7% 10.2% 23.4% 16.6% Incomplete Complete Incomplete Complete Incomplete Complete Incomplete Complete All Cause Revasc MACCE All Cause Revasc MACE
27 META-ANALYSIS OF COMPLETE VS. INCOMPLETE REVASCULARIZATION 27 Pooled PCI Studies Relative Risk [95% CI] p-value Mortality 0.72 [0.64, 0.81] < in patients with multivessel CAD undergoing revascularization with CABG or PCI, CR was associated with lower morbidity and mortality. MI 0.80 [0.71, 0.91] Repeat Revasc 0.72 [0.63, 0.81] < Complete revasc better Incomplete revasc better Garcia et al, JACC Vol. 62, No. 16, 2013
28 IMPELLA CP PUMP DATA SUBMITTED FOR PMA APPROVAL 28 Data from USPella (cvad) registry Analysis of consecutive, unselected patients Impella CP patients enrolled from Jan-Aug 2014 compared with patients submitted to FDA for Impella 2.5 Similar high-risk features of baseline risk. No significant differences in MACCE between patient groups Procedural and Support Characteristics Impella 2.5 (N= 637) Comparative data for patient cohorts Impella CP (N=72) p= Prevalence of CHF 52.80% 69.40% Admitted for AMI 28.40% 38.90% Recommeded for CABG 37.10% 21.10% LM and/or LAD intervention 49.97% 56.80% Treated with rotational atherectomy 16.70% 27.80% Cause of Death Impella 2.5 (N= 637) Impella CP (N=72) Myocardial Infarction 1.26% (8) 2.78% (2) Decompensated Heart/Multi-organ failure 1.1% (7) 0 Procedural complication 0.31% (2) 0 Respiratory failure 0.16% (1) 0 Total 2.83% (18) 2.78% (2) Causes of in-hospital deaths for HRPCI patients supported with Impella 2.5 or Impella CP in Impella Registry. cvad Registry data submitted for FDA Approval
29 29 29 THANK YOU
Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California
High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement
More informationA National Cardiogenic Shock Initiative (CSI):
A National Cardiogenic Shock Initiative (CSI): Insights from the Impella Quality (IQ) Program, cvad Registry and the Detroit CSI Experience William O Neill, MD, FACC Medical Director Structural Heart Disease
More informationHigh Risk PCI for Heart Failure
High Risk PCI for Heart Failure Ray Matthews MD Professor of Clinical Medicine Chief, Division of Cardiovascular Medicine University of Southern California Los Angeles, California Disclosures Abiomed Research
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationRationale for Left Ventricular Support During Percutaneous Coronary Intervention
Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Associate Professor, Division of Cardiology Director, Acute Circulatory Support Program
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationCardiogenic Shock Protocol
Cardiogenic Shock Protocol Impella Devices Best Practices in AMI Cardiogenic Shock Identify 1-3 SBP < 90 mmhg or on inotropes /pressors Cold, clammy, tachycardia Lactate elevated > 2 mmoi /L Stabilize
More informationCLINICAL DOSSIER Protected PCI
CLINICAL DOSSIER Protected PCI with the Impella Heart Pump Executive Summary Protected PCI with the Impella On March 23, 2015, the Impella 2.5 received PMA approval from the U.S. FDA* and on December
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationWho is the high risk patient?
Who is the high risk patient? High risk of periprocedural death or other major complications (hemodynamic compromise, MI, stroke, dialysis) Contributors of Risk Lesion/Procedure Governed by 1. Patient
More informationPercutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
More informationCOURSE OFFERINGS. Committed to Improving Outcomes in Cardiogenic Shock and Protected PCI Through Excellence in Education.
2017 COURSE OFFERINGS Committed to Improving Outcomes in Cardiogenic Shock and Protected PCI Through Excellence in Education. ABOUT THIS COURSE BOOKLET Abiomed offers a full curriculum of educational programs
More informationThe number of patients in the United States with
Treating the Growing Population of Patients With High-Risk, Complex Coronary Artery Disease: Protected PCI With Impella BY SETH BILAZARIAN, MD, FACC, FSCAI The number of patients in the United States with
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationManagement of High-Risk Coronary Artery Disease
Management of High-Risk Coronary Artery Disease Jeffrey J. Popma, MD Director, Interventional Cardiology Clinical Services Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical
More informationCath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology
More informationheadline a Protected PCI Program: Treating the Most Complex Patients
dept Expanding headline Your dept Patient headline Practice dept With headline a Protected PCI Program: Treating the Most Complex Patients deck Protected PCI provides a new treatment option for patients
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationTed Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
More informationABIOMED TCT INVESTOR UPDATE: 2017
ABIOMED TCT INVESTOR UPDATE: 2017 A GROWING POPULATION OF HIGH RISK AND CARDIOGENIC SHOCK PATENTS LEGAL DISCLAIMERS This presentation contains forward-looking statements, including statements regarding
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationCorrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio
Corrective Surgery in Severe Heart Failure Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Session Objectives 1.) Identify which patients with severe
More informationHIGH-RISK, COMPLEX CORONARY ARTERY DISEASE. Treating a Growing Patient Population Using Protected PCI With Impella. Supplement to
Supplement to May/June 2018 HIGH-RISK, COMPLEX CORONARY ARTERY DISEASE Treating a Growing Patient Population Using Protected PCI With Impella TABLE OF CONTENTS 3 Treating the Growing Population of Patients
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationWhat do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
More informationPercutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI
Percutaneous Mechanical Circulatory Support for Cardiogenic Shock 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI The Need for Circulatory Support Basic Pathophysiologic Problems:
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationThe Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize
The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationAssist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationLeft Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France
Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationUseful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?
Preoperative intraaortic balloon counterpulsation in high-risk CABG Stefan Klotz, M.D. Preoperative IABP in high-risk CABG Questions?? Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM Michael Minogue Chairman, President, & CEO LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development of Abiomed's
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationHow to do Primary Angioplasty. - Patients with Cardiogenic Shock
How to do Primary Angioplasty - Patients with Cardiogenic Shock Advanced Cardiovascular Intervention 2011 Dan Blackman Leeds General Infirmary MY CONFLICTS OF INTEREST ARE: Research Grants Medicines Company
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationCORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW
CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationImpella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials
Accepted Manuscript Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials Dagmar M. Ouweneel, MSc, Erlend Eriksen, MD, Melchior Seyfarth,
More informationST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific
More informationAntonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017
Parigi: May 16-19, 2017 Miracor Symposium Speaker: 15 Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy Nothing to disclose PiCSO Impulse System Elective high risk
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationMitigating Operator Risk in Complex Interventional Procedures. Tanveer Rab, MD, FACC Ajay Kirtane, MD, FACC Prashant Kaul, MD, FACC
Mitigating Operator Risk in Complex Interventional Procedures Tanveer Rab, MD, FACC Ajay Kirtane, MD, FACC Prashant Kaul, MD, FACC Risk assessment Documentation Informed consent Public reporting Steps
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationCardiogenic Shock in Acute MI
Cardiogenic Shock in Acute MI Mark Sheldon, MD UNMH Interventional Cardiology Objectives Overview Treatment Definition Shock profiles Causes Medical Mechanical Illustrative case Questions? Revascularization
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationRhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale
A Randomized Clinical Study To Compare The Intra-Aortic Balloon Pump To A Percutaneous Left Atrial-To-Femoral Arterial Bypass Device For Treatment Of Cardiogenic Shock Following Acute Myocardial Infarction.
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationGuidelines/Appropriateness ARCH 2015 St Louis, Missouri April 9-11, 2015 Manish A. Parikh, MD, FACC,FSCAI
Guidelines/Appropriateness ARCH 2015 St Louis, Missouri April 9-11, 2015 Manish A. Parikh, MD, FACC,FSCAI Center for Interventional Vascular Therapy Columbia University Medical Center / New York Presbyterian
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationMEDICAL POLICY SUBJECT: TRANSMYOCARDIAL REVASCULARIZATION
MEDICAL POLICY SUBJECT: TRANSMYOCARDIAL 7/21/05, 05/18/06, 03/15/07, 02/21/08,, PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM Michael Minogue Chairman, President, & CEO January 8, 2018 LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationManagement of High-Risk CAD : Surgeons Perspective
Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationRevascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationhigh SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
More informationInstantaneous Wave-Free Ratio
Instantaneous Wave-Free Ratio Alejandro Aquino MD Interventional Cardiology Fellow Washington University in St. Louis Barnes-Jewish Hospital Instantaneous Wave-Free Ratio Alejandro Aquino MD Disclosure
More informationΟξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας
Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας ACUTE HEART FAILURE AND CAD: ACS / LV ischaemic dysfunction Mechanical complications
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationIs bypass surgery needed for elderly patients with LMT disease? From the surgical point of view
CCT 2003 (Kobe) Is bypass surgery needed for elderly patients with LMT disease? From the surgical point of view Hitoshi Yaku, MD, PhD Department of Cardiovascular Surgery Kyoto Prefectural University of
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 OSPEDALE Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationCPORT E Trial. Atlantic C PORT
CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program
More information